Microbiology of the pneumococcal infections: Antibiotic resistance;Microbiología de las infecciones neumocócicas. Resistencia a los antibióticos

Anales de Pediatria Monografias

Volumn 1, Issue 2, 2003, Pages 3-13

  Picazo, J J ^a   Betriu, C ^a   Gonzalez Romo F ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; PENICILLIN BINDING PROTEIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; REVIEW; SPAIN; STREPTOCOCCUS INFECTION; VIRUS;

EID: 28844488567     PISSN: 16962737     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Romero J, Sánchez A, Corral O, Rubio M, Picazo JJ. Estudio de las infecciones pediátricas en el medio extrahospitalario. An Esp Pediatr 1994;(Supl 63):112-6.
2. Del Castillo F, García Perea A, Baquero Artigao F. Bacteriology of acute otitis media in Spain: a prospective study based on tympanocentesis. Pediatr Infect Dis J 1996;15:541-3.
3. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992;11(8 Suppl):S7-11.
4. Nash D, Wald E. Sinusitis. Pediatr Rev 2001;22:111-7.
5. World Health Organization. Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rec 1999;74:177-84.
6. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
7. Gómez J, Baños V, Ruiz Gómez J, Soto MC, Muñoz L, Núñez ML, et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996;15:556-60.
8. Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000;19:293-8.
9. Pineda V, Pérez A, Domingo M, Larramona H, Segura F, Fontanals D. Neumonía neumocócica bacteriémica. An Esp Pediatr 2002;57:408-13.
10. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-35.
11. Ewig S, Ruiz M, Torres A, Marco F, Martínez JA, Sánchez M, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835-42.
12. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997;337:970-6.
13. Moraga FA. Espectro clínico de la infección neumocócica. An Esp Pediatr 2002;56:34-43.
14. Casado J, Fenoll A, Aristegui J, Rodrigo de Liria C, Martinón JM, Berrón S, et al. Neumocócica GpeEdlM. Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico. An Esp Pediatr 2002;57:295-300.
15. Urwin G, Yuan MF, Hall LM, Brown K, Efstratiou A, Feldman RA. Pneumococcal meningitis in the North East Thames Region UK: epidemiology and molecular analysis of isolates. Epidemiol Infect 1996;117:95-102.
16. Kornelisse RF, Westerbeek CM, Spoor AB, Van der Heijde B, Spanjaard L, Neijens HJ, et al. Pneumococcal meningitis in children: prognostic indicators and outcome. Clin Infect Dis 1995;21:1390-7.
17. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infantsand young children: recomendations of the Advisory Commitee on Inmunization Practice (ACIP). MMWR 2000;49:1-38.
18. NCCLS. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. Documento M 100-S13 (M7). Wayne: National Committee for Clinical Laboratory Standards, 2003.
19. Kislak JW, Razavi LM, Daly AK, Finland M. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 1965;250:261-8.
20. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967;2:264-5.
21. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
22. Fenoll A, Jado I, Vicioso D, Pérez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol 1998;36:3447-54.
23. Liñares J, Pallares R, Alonso T, Pérez JL, Ayats J, Gudiol F, et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis 1992;15:99-105.
24. Baquero F, García Rodríguez JA, García de Lomas J, Aguilar L. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999;43:357-9.
25. Oteo J, Cruchaga S, Campos J, Sáez Nieto JA, Baquero F. Resistencia a antibióticos en 622 Streptococcus pneumoniae aislados de líquidos cefalorraquídeo y sangre en 33 hospitales españoles en la Red Europea de Vigilancia de Resistencia a Antibióticos (2000). Enferm Infecc Microbiol Clin 2003;21:12-9.
26. Navarro C, Egido P, Aspiroz C, Duran E, García C, Rubio C, et al. Resistencia a penicilina y otros antimicrobianos en 301 aislamientos clínicos de Streptococcus pneumoniae. Enferm Infecc Microbiol Clin 2000;18:314-8.
27. García-Martos P, Galán F, Marín P, Mira J. Increase in high resistance to penicillin of clinical isolates of Streptococcus pneumoniae in Cádiz, Spain. Chemotherapy 1997;43:179-81.
28. Marton A, Gulyas M, Muñoz R, Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis 1991;163:542-8.
29. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in the United States during 1999-2000, Including a Comparison of Resistance Rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
30. Sisson BA, Buck G, Franco SM, Goldsmith LJ, Rabalais GP. Penicillin minimum inhibitory concentration drift in identical sequential Streptococcus pneumoniae isolates from colonized healthy infants. Clin Infect Dis 2000;30:191-4.
31. Baquero F, Martínez Beltran J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991;28(Suppl C):31-8.
32. Del Castillo F, Baquero Artigao F, García Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain. Pediatr Infect Dis J 1998;17:94-7.
33. Catalán MJ, Fernández JM, Vázquez A, Varela de Seijas E, Suárez A, Bernaldo de Quirós JC. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis 1994;18:766-9.
34. Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9.
35. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-3.
36. Liñares J, De la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;341:1546-7; discussion 1547-8.
37. Yokota S, Sato K, Kuwahara O, Habadera S, Tsukamoto N, Ohuchi H, et al. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 2002;46:3311-5.
38. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000;181:369-73.
39. Henriques Normark B, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 2001;32:552-8.
40. Antón N, Blázquez R, Gómez Garcés JL, Alós JI. Study of vancomycin tolerance in 120 strains of Streptococcus pneumoniae isolated in 1999 in Madrid, Spain. J Antimicrob Chemother 2001;47:902-3.
41. Ortega M, Marco F, Soriano A, García E, Martínez JA, Mensa J. Lack of Vancomycin Tolerance in Streptococcus pneumoniae Strains Isolated in Barcelona, Spain, from 1999 to 2001. Antimicrob Agents Chemother 2003;47:1976-8.
42. Marco F, Bouza E, García de Lomas J, Aguilar L. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: the impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. The Spanish Surveillance Group for Respiratory Pathogens. J Antimicrob Chemother 2000;46:557-64.
43. Karlowsky JA, Thornsberry C, Critchley IA, Jones ME, Evangelista AT, Noel GJ, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 2003;47:1790-7.
44. Gehanno P, Lenoir G, Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 1995;39:271-2.
45. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999;29:321-7.
46. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8.
47. Harwell JI, Brown RB. The drug-resistant pneumococcus: clinical relevance, therapy, and prevention. Chest 2000;117:530-41.
48. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
49. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995;171:885-9.
50. Hausdorff WP. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr 2002;161(Suppl 2):S135-9.
51. Von Kries R, Hermann M, Al Lahham A, Siedler A, Reinert RR. Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial? Eur J Pediatr 2002;161(Suppl 2):S140-3.
52. Joloba ML, Windau A, Bajaksouzian S, Appelbaum PC, Hausdorff WP, Jacobs MR. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis 2001;33:1489-94.
53. Black S, Shinefield H. Safety and efficacy of the sevenvalent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr 2002;161(Suppl 2):S127-31.
54. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-5.
55. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
56. Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
57. Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000;160:2633-8.
58. Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002;51:98-104.
59. Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996;174:1352-5.
60. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
61. Geslin P, Fremaux A, Sissia G, Spicq C. Streptococcus pneumoniae: sérotypes, souches invasives et résistantes aux antibiotiques. Situation actuelle en France. Presse Med 1998;27(Suppl 1):21-7.
62. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000;30:122-40.
63. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21.
64. Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283:1460-8.
65. Giebink GS. The prevention of pneumococcal disease in children. N Engl J Med 2001;345:1177-83.